The regulatory roles of ROCK and MRCK kinases in the plasticity of cancer cell migration

Cancer Letters

Volumn 361, Issue 2, 2015, Pages 185-196

  Kale, Vijay Pralhad ^a   Hengst, Jeremy A ^a   Desai, Dhimant H ^a   Amin, Shantu G ^a   Yun, Jong K ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Anticancer therapeutics; Cell migration plasticity; MRCK; Polypharmacology; Rho kinase; ROCK and MRCK inhibitors

Indexed keywords

MATRIX METALLOPROTEINASE; MYOTONIC DYSTROPHY KINASE RELATED CDC42 BINDING KINASE; PHOSPHOTRANSFERASE; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE 1; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE 2; UNCLASSIFIED DRUG; PROTEIN SERINE THREONINE KINASE; RHO KINASE;

CANCER CELL LINE; CELL MIGRATION; CELL PROLIFERATION; DICTYOSTELIUM DISCOIDEUM; ENZYME REGULATION; HUMAN; MESENCHYME CELL; METASTASIS; NONHUMAN; PHARMACOLOGICAL BLOCKING; PLASTICITY; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; CELL MOTION; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

CELL MOVEMENT; HUMANS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84926089061     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.03.017     Document Type: Review

References (155)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
3. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
4. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med 2006, 12:895-904.
5. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
6. Elvin P., Garner A.P. Tumour invasion and metastasis: challenges facing drug discovery. Curr. Opin. Pharmacol 2005, 5:374-381.
7. Sahai E. Mechanisms of cancer cell invasion. Curr. Opin. Genet. Dev 2005, 15:87-96.
8. Unbekandt M., Olson M.F. The actin-myosin regulatory MRCK kinases: regulation, biological functions and associations with human cancer. J. Mol. Med. (Berl.) 2014, 92:217-225.
9. Pandey M.K., Rastogi S., Kale V.P., Gowda T., Amin S.G. Targeting CXCL12/CXCR4 axis in multiple myeloma. J. Hematol. Thromb. Dis 2014, 2:10.
10. Sahai E., Marshall C.J. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat. Cell Biol 2003, 5:711-719.
11. Wolf K., Mazo I., Leung H., Engelke K., von Andrian U.H., Deryugina E.I., et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol 2003, 160:267-277.
12. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
13. Wickman G.R., Samuel M.S., Lochhead P.A., Olson M.F. The Rho-regulated ROCK kinases in cancer. Rho GTPases in Cancer 2010, 163-192. Springer, New York, (Online). K. van Golen (Ed.).
14. Julian L., Olson M.F. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases 2014, 5. e29846.
15. Wilkinson S., Paterson H.F., Marshall C.J. Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat. Cell Biol 2005, 7:255-261.
16. Pan P., Shen M., Yu H., Li Y., Li D., Hou T. Advances in the development of Rho-associated protein kinase (ROCK) inhibitors. Drug Discov. Today 2013, 18:1323-1333.
17. Pearce L.R., Komander D., Alessi D.R. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol 2010, 11:9-22.
18. Ishizaki T., Maekawa M., Fujisawa K., Okawa K., Iwamatsu A., Fujita A., et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996, 15:1885-1893.
19. Matsui T., Amano M., Yamamoto T., Chihara K., Nakafuku M., Ito M., et al. Rho-associated kinase, a novel serine threonine kinase, as a putative target for the small GTP binding protein Rho. EMBO J. 1996, 15:2208-2216.
20. Nakagawa O., Fujisawa K., Ishizaki T., Saito Y., Nakao K., Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996, 392:189-193.
21. Zhao Z.-S., Manser E. PAK and other Rho-associated kinases - effectors with surprisingly diverse mechanisms of regulation. Biochem. J. 2005, 386:201-214.
22. Leung T., Chen X.Q., Tan I., Manser E., Lim L. Myotonic dystrophy kinase-related Cdc42-binding kinase acts as a Cdc42 effector in promoting cytoskeletal reorganization. Mol. Cell. Biol 1998, 18:130-140.
23. Riento K., Ridley A.J. Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol 2003, 4:446-456.
24. Amano M., Nakayama M., Kaibuchi K. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken) 2010, 67:545-554.
25. Tojkander S., Gateva G., Lappalainen P. Actin stress fibers - assembly, dynamics and biological roles. J. Cell Sci 2012, 125:1855-1864.
26. Ishizaki T., Naito M., Fujisawa K., Maekawa M., Watanabe N., Saito Y., et al. p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett 1997, 404:118-124.
27. Chrzanowska-Wodnicka M., Burridge K. Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J. Cell Biol 1996, 133:1403-1415.
28. Amano M., Chihara K., Kimura K., Fukata Y., Nakamura N., Matsuura Y., et al. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 1997, 275:1308-1311.
29. Leung T., Chen X.Q., Manser E., Lim L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell. Biol 1996, 16:5313-5327.
30. Tapon N., Hall A. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr. Opin. Cell Biol 1997, 9:86-92.
31. Parri M., Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun. Signal 2010, 8:23.
32. Ridley A.J., Hall A. The small Gtp-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth-factors. Cell 1992, 70:389-399.
33. Nobes C.D., Hall A. Rho, RAC, and CDC42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995, 81:53-62.
34. Olson M.F., Sahai E. The actin cytoskeleton in cancer cell motility. Clin. Exp. Metastasis 2009, 26:273-287.
35. Otomo T., Otomo C., Tomchick D.R., Machius M., Rosen M.K. Structural basis of Rho GTPase-mediated activation of the formin mDia1. Mol. Cell 2005, 18:273-281.
36. Amano M., Ito M., Kimura K., Fukata Y., Chihara K., Nakano T., et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol. Chem 1996, 271:20246-20249.
37. Kimura K., Ito M., Amano M., Chihara K., Fukata Y., Nakafuku M., et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996, 273:245-248.
38. Ohashi K., Nagata K., Maekawa M., Ishizaki T., Narumiya S., Mizuno K. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J. Biol. Chem 2000, 275:3577-3582.
39. Sumi T., Matsumoto K., Takai Y., Nakamura T. Cofilin phosphorylation and actin cytoskeletal dynamics regulated by Rho- and Cdc42-activated LIM-kinase 2. J. Cell Biol 1999, 147:1519-1532.
40. Maekawa M., Ishizaki T., Boku S., Watanabe N., Fujita A., Iwamatsu A., et al. Signaling from rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999, 285:895-898.
41. Tan I., Ng C.H., Lim L., Leung T. Phosphorylation of a novel myosin binding subunit of protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton. J. Biol. Chem 2001, 276:21209-21216.
42. Vicente-Manzanares M., Ma X., Adelstein R.S., Horwitz A.R. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat. Rev. Mol. Cell Biol 2009, 10:778-790.
43. Scott R.W., Olson M.F. LIM kinases: function, regulation and association with human disease. J. Mol. Med 2007, 85:555-568.
44. Nakamura N., Oshiro N., Fukata Y., Amano M., Fukata M., Kuroda S., et al. Phosphorylation of ERM proteins at filopodia induced by Cdc42. Genes Cells 2000, 5:571-581.
45. Katoh K., Kano Y., Noda Y. Rho-associated kinase-dependent contraction of stress fibres and the organization of focal adhesions. J. R. Soc. Interface 2011, 8:305-311.
46. Kimura K., Fukata Y., Matsuoka Y., Bennett V., Matsuura Y., Okawa K., et al. Regulation of the association of adducin with actin filaments by Rho-associated kinase (Rho-kinase) and myosin phosphatase. J. Biol. Chem 1998, 273:5542-5548.
47. Matsui T. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J. Cell Biol 1998, 140:647-657.
48. Kosako H., Goto H., Yanagida M., Matsuzawa K., Fujita M., Tomono Y., et al. Specific accumulation of Rho-associated kinase at the cleavage furrow during cytokinesis: cleavage furrow-specific phosphorylation of intermediate filaments. Oncogene 1999, 18:2783-2788.
49. Goto H., Kosako H., Tanabe K., Yanagida M., Sakurai M., Amano M., et al. Phosphorylation of vimentin by Rho-associated kinase at a unique amino-terminal site that is specifically phosphorylated during cytokinesis. J. Biol. Chem 1998, 273:11728-11736.
50. Kosako H., Amano M., Yanagida M., Tanabe K., Nishi Y., Kaibuchi K., et al. Phosphorylation of glial fibrillary acidic protein at the same sites by cleavage furrow kinase and Rho-associated kinase. J. Biol. Chem 1997, 272:10333-10336.
51. Schofield A.V., Gamell C., Suryadinata R., Sarcevic B., Bernard O. Tubulin polymerization promoting protein 1 (Tppp1) phosphorylation by Rho-associated coiled-coil kinase (rock) and cyclin-dependent kinase 1 (Cdk1) inhibits microtubule dynamics to increase cell proliferation. J. Biol. Chem 2013, 288:7907-7917.
52. Schofield A.V., Steel R., Bernard O. Rho-associated coiled-coil kinase (ROCK) protein controls microtubule dynamics in a novel signaling pathway that regulates cell migration. J. Biol. Chem 2012, 287:43620-43629.
53. Tokesi N., Lehotzky A., Horvath I., Szabo B., Olah J., Lau P., et al. TPPP/p25 promotes tubulin acetylation by inhibiting histone deacetylase 6. J. Biol. Chem 2010, 285:17896-17906.
54. Morgan-Fisher M., Wewer U.M., Yoneda A. Regulation of ROCK activity in cancer. J. Histochem. Cytochem 2013, 61:185-198.
55. Abe H., Kamai T., Tsujii T., Nakamura F., Mashidori T., Mizuno T., et al. Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed. Res 2008, 29:155-161.
56. Zohrabian V.M., Forzani B., Chau Z., Murali R., Jhanwar-Uniyal M. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res 2009, 29:119-123.
57. Wong C.C.-L., Wong C.-M., Tung E.K.-K., Man K., Ng I.O.-L. Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology 2009, 49:1583-1594.
58. Kamai T., Arai K., Sumi S., Tsujii T., Honda M., Yamanishi T., et al. The rho/rho-kinase pathway is involved in the progression of testicular germ cell tumour. BJU Int 2002, 89:449-453.
59. Kamai T., Arai K., Tsujii T., Honda M., Yoshida K. Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int 2001, 87:227-231.
60. Kamai T., Tsujii T., Arai K., Takagi K., Asami H., Ito Y., et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res 2003, 9:2632-2641.
61. Kamai T., Yamanishi T., Shirataki H., Takagi K., Asami H., Ito Y., et al. Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin. Cancer Res 2004, 10:4799-4805.
62. Lane J., Martin T.A., Watkins G., Mansel R.E., Jiang W.G. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int. J. Oncol 2008, 33:585-593.
63. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
64. Forbes S.A., Bhamra G., Bamford S., Dawson E., Kok C., Clements J., et al. The catalogue of somatic mutations in cancer (COSMIC). Current Protocols in Human Genetics/Editorial Board 2008, Chapter 10, Wiley, Unit 10 11. J.L. Haines (Ed.).
65. Forbes S.A., Tang G., Bindal N., Bamford S., Dawson E., Cole C., et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010, 38:D652-D657.
66. Lochhead P.A., Wickman G., Mezna M., Olson M.F. Activating ROCK1 somatic mutations in human cancer. Oncogene 2010, 29:2591-2598.
67. Liu S., Goldstein R.H., Scepansky E.M., Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009, 69:8742-8751.
68. Vigil D., Kim T.Y., Plachco A., Garton A.J., Castaldo L., Pachter J.A., et al. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res 2012, 72:5338-5347.
69. Heikkila T., Wheatley E., Crighton D., Schroder E., Boakes A., Kaye S.J., et al. Co-crystal structures of inhibitors with MRCKbeta, a key regulator of tumor cell invasion. PLoS ONE 2011, 6. e24825.
70. Unbekandt M., Croft D.R., Crighton D., Mezna M., McArthur D., McConnell P., et al. A novel small-molecule MRCK inhibitor blocks cancer cell invasion. Cell Commun. Signal 2014, 12:54.
71. Zhao Y., Loyer P., Li H., Valentine V., Kidd V., Kraft A.S. Cloning and chromosomal location of a novel member of the myotonic dystrophy family of protein kinases. J. Biol. Chem 1997, 272:10013-10020.
72. Sahai E. Illuminating the metastatic process. Nat. Rev. Cancer 2007, 7:737-749.
73. Kimlin L.C., Casagrande G., Virador V.M. In vitro three-dimensional (3D) models in cancer research: an update. Mol. Carcinog 2013, 52:167-182.
74. Hooper S., Marshall J.F., Sahai E. Tumor cell migration in three dimensions. Methods Enzymol 2006, 406:625-643.
75. Pinner S., Sahai E. Imaging amoeboid cancer cell motility in vivo. J. Microsc 2008, 231:441-445.
76. Condeelis J., Segall J.E. Intravital imaging of cell movement in tumours. Nat. Rev. Cancer 2003, 3:921-930.
77. Wolf K., Alexander S., Schacht V., Coussens L.M., von Andrian U.H., van Rheenen J., et al. Collagen-based cell migration models in vitro and in vivo. Semin. Cell Dev. Biol 2009, 20:931-941.
78. Entenberg D., Kedrin D., Wyckoff J., Sahai E., Condeelis J., Segall J.E. Imaging tumor cell movement in vivo. Current Protocols in Cell Biology/Editorial Board 2013, Chapter 19, Wiley, Unit19 17. J.S. Bonifacino (Ed.).
79. Kedrin D., Wyckoff J., Sahai E., Condeelis J., Segall J.E. Imaging tumor cell movement in vivo. Current Protocols in Cell Biology/Editorial Board 2007, Chapter 19, Wiley, Unit 19 17. J.S. Bonifacino (Ed.).
80. Friedl P., Sahai E., Weiss S., Yamada K.M. New dimensions in cell migration. Nat. Rev. Mol. Cell Biol 2012, 13:743-747.
81. Zimmermann M., Box C., Eccles S.A. Two-dimensional vs. three-dimensional in vitro tumor migration and invasion assays. Methods Mol. Biol 2013, 986:227-252.
82. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147:992-1009.
83. Friedl P., Wolf K. Plasticity of cell migration: a multiscale tuning model. J. Cell Biol 2010, 188:11-19.
84. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
85. Pankova K., Rosel D., Novotny M., Brabek J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell. Mol. Life Sci 2010, 67:63-71.
86. Tsai J.H., Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 2013, 27:2192-2206.
87. Fisher K.E., Sacharidou A., Stratman A.N., Mayo A.M., Fisher S.B., Mahan R.D., et al. MT1-MMP- and Cdc42-dependent signaling co-regulate cell invasion and tunnel formation in 3D collagen matrices. J. Cell Sci 2009, 122:4558-4569.
88. Vial E., Sahai E., Marshall C.J. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003, 4:67-79.
89. Ridley A.J., Schwartz M.A., Burridge K., Firtel R.A., Ginsberg M.H., Borisy G., et al. Cell migration: integrating signals from front to back. Science 2003, 302:1704-1709.
90. Friedl P., Borgmann S., Brocker E.B. Amoeboid leukocyte crawling through extracellular matrix: lessons from the Dictyostelium paradigm of cell movement. J. Leukoc. Biol 2001, 70:491-509.
91. Wyckoff J.B., Pinner S.E., Gschmeissner S., Condeelis J.S., Sahai E. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr. Biol 2006, 16:1515-1523.
92. Kosla J., Pankova D., Plachy J., Tolde O., Bicanova K., Dvorak M., et al. Metastasis of aggressive amoeboid sarcoma cells is dependent on Rho/ROCK/MLC signaling. Cell Commun. Signal 2013, 11:51.
93. Fackler O.T., Grosse R. Cell motility through plasma membrane blebbing. J. Cell Biol 2008, 181:879-884.
94. Pinner S., Sahai E. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat. Cell Biol 2008, 10:127-137.
95. Lammermann T., Sixt M. Mechanical modes of 'amoeboid' cell migration. Curr. Opin. Cell Biol 2009, 21:636-644.
96. Friedl P., Locker J., Sahai E., Segall J.E. Classifying collective cancer cell invasion. Nat. Cell Biol 2012, 14:777-783.
97. Ilina O., Friedl P. Mechanisms of collective cell migration at a glance. J. Cell Sci 2009, 122:3203-3208.
98. Pitts W.C., Rojas V.A., Gaffey M.J., Rouse R.V., Esteban J., Frierson H.F., et al. Carcinomas with metaplasia and sarcomas of the breast. Am. J. Clin. Pathol 1991, 95:623-632.
99. Sood A.K., Seftor E.A., Fletcher M.S., Gardner L.M.G., Heidger P.M., Buller R.E., et al. Molecular determinants of ovarian cancer plasticity. Am. J. Pathol 2001, 158:1279-1288.
100. Nabeshima K., Inoue T., Shimao Y., Kataoka H., Koono M. Cohort migration of carcinoma cells: differentiated colorectal carcinoma cells move as coherent cell clusters or sheets. Histol. Histopathol 1999, 14:1183-1197.
101. Khalil A.A., Friedl P. Determinants of leader cells in collective cell migration. Integr. Biol. (Camb.) 2010, 2:568-574.
102. Friedl P., Wolf K., Zegers M.M. Rho-directed forces in collective migration. Nat. Cell Biol 2014, 16:208-210.
103. Reffay M., Parrini M.C., Cochet-Escartin O., Ladoux B., Buguin A., Coscoy S., et al. Interplay of RhoA and mechanical forces in collective cell migration driven by leader cells. Nat. Cell Biol 2014, 16:217-223.
104. Rorth P. Collective cell migration. Annu. Rev. Cell Dev. Biol 2009, 25:407-429.
105. Wolf K., Wu Y.I., Liu Y., Geiger J., Tam E., Overall C., et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat. Cell Biol 2007, 9:893-904.
106. Nabeshima K., Inoue T., Shimao Y., Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol. Int 2002, 52:255-264.
107. Friedl P., Wolf K. Tube travel: the role of proteases in individual and collective a cancer cell invasion. Cancer Res 2008, 68:7247-7249.
108. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol 2007, 9:1392-1400.
109. Friedl P., Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat. Rev. Mol. Cell Biol 2009, 10:445-457.
110. Carragher N.O., Walker S.M., Carragher L.S.A., Harris F., Sawyer T.K., Brunton V.G., et al. Calpain 2 and Src dependence distinguishes mesenchymal and amoeboid modes of tumour cell invasion: a link to integrin function. Oncogene 2006, 25:5726-5740.
111. Friedl P., Hegerfeldt Y., Tusch M. Collective cell migration in morphogenesis and cancer. Int. J. Dev. Biol 2004, 48:441-449.
112. Hegerfeldt Y., Tusch M., Brocker E.B., Friedl P. Collective cell movement in primary melanoma explants: plasticity of cell-cell interaction, ss 1-integrin function, and migration strategies. Cancer Res 2002, 62:2125-2130.
113. Yamazaki D., Kurisu S., Takenawa T. Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. Oncogene 2009, 28:1570-1583.
114. Sanz-Moreno V., Gadea G., Ahn J., Paterson H., Marra P., Pinner S., et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008, 135:510-523.
115. Croft D.R., Olson M.F. Regulating the conversion between rounded and elongated modes of cancer cell movement. Cancer Cell 2008, 14:349-351.
116. Wang H.R., Ogunjimi A.A., Zhang Y., Ozdamar B., Bose R., Wrana J.L. Degradation of RhoA by Smurf1 ubiquitin ligase. Methods Enzymol 2006, 406:437-447.
117. Sahai E., Garcia-Medina R., Pouyssegur J., Vial E. Smurf1 regulates tumor cell plasticity and motility through degradation of RhoA leading to localized inhibition of contractility. J. Cell Biol 2007, 176:35-42.
118. Zaman M.H., Trapani L.M., Siemeski A., MacKellar D., Gong H.Y., Kamm R.D., et al. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:10889-10894.
119. Sabeh F., Shimizu-Hirota R., Weiss S.J. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J. Cell Biol 2009, 185:11-19.
120. Starke J., Wehrle-Haller B., Friedl P. Plasticity of the actin cytoskeleton in response to extracellular matrix nanostructure and dimensionality. Biochem. Soc. Trans 2014, 42:1356-1366.
121. Petrie R.J., Gavara N., Chadwick R.S., Yamada K.M. Nonpolarized signaling reveals two distinct modes of 3D cell migration. J. Cell Biol 2012, 197:439-455.
122. Wong I.Y., Javaid S., Wong E.A., Perk S., Haber D.A., Toner M., et al. Collective and individual migration following the epithelial-mesenchymal transition. Nat. Mater 2014, 13(11):1063-1071.
123. Haeger A., Krause M., Wolf K., Friedl P. Cell jamming: collective invasion of mesenchymal tumor cells imposed by tissue confinement. Biochim. Biophys. Acta 1840, 2014:2386-2395.
124. Stroka K.M., Gu Z., Sun S.X., Konstantopoulos K. Bioengineering paradigms for cell migration in confined microenvironments. Curr. Opin. Cell Biol 2014, 30C:41-50.
125. Balzer E.M., Tong Z., Paul C.D., Hung W.C., Stroka K.M., Boggs A.E., et al. Physical confinement alters tumor cell adhesion and migration phenotypes. FASEB J. 2012, 26:4045-4056.
126. Stroka K.M., Jiang H., Chen S.H., Tong Z., Wirtz D., Sun S.X., et al. Water permeation drives tumor cell migration in confined microenvironments. Cell 2014, 157:611-623.
127. Fidler I.J. Timeline - the pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
128. Wells A., Grahovac J., Wheeler S., Ma B., Lauffenburger D. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol. Sci 2013, 34:283-289.
129. Lauffenburger D.A., Horwitz A.F. Cell migration: a physically integrated molecular process. Cell 1996, 84:359-369.
130. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst 2001, 93:178-193.
131. Mehta K., Gandhi V., Pathak S., Aggarwal B.B., Grover R.K. Multi-targeted approach to cancer treatment: an international translational cancer research symposium. Anticancer Res 2014, 34:6791-6795.
132. Zarebczan B., Chen H. Multi-targeted approach in the treatment of thyroid cancer. Minerva Chir 2010, 65:59-69.
133. Lu J.J., Pan W., Hu Y.J., Wang Y.T. Multi-target drugs: the trend of drug research and development. PLoS ONE 2012, 7. e40262.
134. Somlyo A.V., Phelps C., Dipierro C., Eto M., Read P., Barrett M., et al. Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J. 2003, 17:223-234.
135. Igishi T., Mikami M., Murakami K., Matsumoto S., Shigeoka Y., Nakanishi H., et al. Enhancement of cisplatin-induced cytotoxicity by ROCK inhibitor through suppression of focal adhesion kinase-independent mechanism in lung carcinoma cells. Int. J. Oncol 2003, 23:1079-1085.
136. Street C.A., Routhier A.A., Spencer C., Perkins A.L., Masterjohn K., Hackathorn A., et al. Pharmacological inhibition of Rho-kinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells. Int. J. Oncol 2010, 37:1297-1305.
137. Sanz-Moreno V. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 2011, 20:229-245.
138. Rao J.Y., Li N. Microfilament actin remodeling as a potential target for cancer drug development. Curr. Cancer Drug Targets 2004, 4:345-354.
139. Rath N., Olson M.F. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep 2012, 13:900-908.
140. Feng Y., LoGrasso P.V. Rho kinase inhibitors: a patent review (2012-2013). Expert Opin. Ther. Pat 2014, 24:295-307.
141. Hahmann C., Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell. Mol. Life Sci 2010, 67:171-177.
142. Liao J.K., Seto M., Noma K. Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol 2007, 50:17-24.
143. Lowe H.I., Watson C.T., Badal S., Toyang N.J., Bryant J. Cycloartane-3,24,25-triol inhibits MRCKalpha kinase and demonstrates promising anti prostate cancer activity in vitro. Cancer Cell Int 2012, 12:46.
144. Tan I., Lai J., Yong J., Li S.F., Leung T. Chelerythrine perturbs lamellar actomyosin filaments by selective inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase. FEBS Lett 2011, 585:1260-1268.
145. Kale V.P., Hengst J.A., Desai D.H., Dick T.E., Choe K.N., Colledge A.L., et al. A novel selective multikinase inhibitor of ROCK and MRCK effectively blocks cancer cell migration and invasion. Cancer Lett 2014, 354(2):299-310.
146. Shen M., Yu H., Li Y., Li P., Pan P., Zhou S., et al. Discovery of Rho-kinase inhibitors by docking-based virtual screening. Mol. Biosyst 2013, 9:1511-1521.
147. Shibuya M., Asano T., Sasaki Y. Effect of fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm. Acta Neurochir. Suppl 2001, 77:201-204.
148. Watanabe K., Ueno M., Kamiya D., Nishiyama A., Matsumura M., Wataya T., et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol 2007, 25:681-686.
149. Castro D.J., Maurer J., Hebbard L., Oshima R.G. ROCK1 inhibition promotes the self-renewal of a novel mouse mammary cancer stem cell. Stem Cells 2013, 31:12-22.
150. Zhang L., Valdez J.M., Zhang B.Y., Wei L., Chang J.A., Xin L. ROCK Inhibitor Y-27632 suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells and increases their cloning efficiency. PLoS ONE 2011, 6.
151. Ohata H., Ishiguro T., Aihara Y., Sato A., Sakai H., Sekine S., et al. Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells. Cancer Res 2012, 72:5101-5110.
152. Liu X., Ory V., Chapman S., Yuan H., Albanese C., Kallakury B., et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol 2012, 180:599-607.
153. Suprynowicz F.A., Upadhyay G., Krawczyk E., Kramer S.C., Hebert J.D., Liu X., et al. Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:20035-20040.
154. Yang S., Kim H.M. ROCK inhibition activates MCF-7 cells. PLoS ONE 2014, 9. e88489.
155. Vishnubhotla R., Bharadwaj S., Sun S., Metlushko V., Glover S.C. Treatment with Y-27632, a ROCK Inhibitor, increases the proinvasive nature of SW620 cells on 3D collagen type 1 matrix. Int. J. Cell Biol 2012, 2012. 259142.